ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 809

Prevalence and Distribution of Vascular FDG Uptake on Positron Emission Tomography (PET)-CT in Patients Suspected of Having Giant Cell Arteritis – Interim Results from the Giant Cell Arteritis and PET Scan (GAPS) Study

Anthony Sammel1, Edward Hsiao2, Katherine Nguyen3, Geoffrey Schembri2, Leslie Schrieber3, Peter Youssef4, Beatrice Janssen3 and Rodger Laurent3, 1Rheumatology, Royal North Shore Hospital, St Leonards, Sydney, Australia, 2Royal North Shore Hospital, St Leonards, Australia, 3Royal North Shore Hospital, St Leonards, Sydney, Australia, 4Royal Prince Alfred Hospital, Camperdown, Sydney, Australia

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: giant cell arteritis, Imaging, positron emission tomography (PET) and vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Vasculitis Poster I: Large Vessel Vasculitis

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Positron emission tomography (PET)-CT scan can assess large vessel vasculitis in giant cell arteritis (GCA). It has a reported sensitivity of 80% for biopsy positive disease but the superficial temporal, occipital and vertebral arteries have not previously been assessed due to difficulties with spatial resolution.

Methods: 41 patients suspected of having GCA between May 2016 and April 2017 underwent fluorine-18 fluoro-2-deoxyglucose (FDG) time-of-flight PET-CT scan within 72 hours of commencing corticosteroids and before clinically guided temporal artery biopsy (TAB). Patients were imaged from the vertex of the head to the diaphragm with 1mm CT slice reconstruction. FDG uptake was graded at 16 vascular sites using a semi-quantitative scale defined as zero (less than or equal to blood pool), one (minimally increased), two (clearly increased) or three (very marked uptake) by one of two blinded, experienced nuclear medicine physicians. Arterial calcification, shoulder region FDG uptake, infection and cancer were also reported.

Results: Mean age was 70 and 29 (71%) were female. Headache (88%), jaw claudication (34%), PMR (32%) and visual disturbance (29%) were common reported symptoms. Median CRP was 16 mg/L (range 1 – 299) and ESR was 36 mm/hr (range 5 – 130). Eight (20%) patients had mural inflammation on biopsy, four (10%) had limited periadventitial small vessel vasculitis and one had unequivocal thoracic aortitis on CT scan and did not undergo TAB. 28 (68%) had negative biopsies. 30 (73%) met the 1990 ACR criteria for GCA and 18 (44%) were assessed by the treating clinician as having definite or probable (>= 50% chance) GCA at two-week follow-up. 28 (68%) had at least grade one uptake in one or more vascular territory and 14 (34%) had at least grade two uptake. The carotid (44%), vertebral (32%) and superficial temporal (27%) arteries were the most affected. 6 (15%) patients had increased uptake isolated to the vertebral, temporal or occipital arteries. Shoulder region uptake was detected in 23 (56%) of patients, infection in three (two sinusitis, one pneumonia) and lung cancer in three. Vascular calcification did not globally correlate with increased FDG uptake (Spearman’s correlation coefficient = 0.05).

Conclusion: 68% of patients initially suspected of having GCA had at least mild increased FDG uptake on PET-CT scan. This compared with only 30% with inflammatory changes on biopsy. Increased uptake was commonly seen in the vertebral and temporal arteries which have not previously been assessed in PET-CT studies. Long-term follow-up will determine the clinical role of this protocol in GCA. 


Disclosure: A. Sammel, Arthritis Australia, 2; E. Hsiao, None; K. Nguyen, None; G. Schembri, None; L. Schrieber, None; P. Youssef, None; B. Janssen, None; R. Laurent, None.

To cite this abstract in AMA style:

Sammel A, Hsiao E, Nguyen K, Schembri G, Schrieber L, Youssef P, Janssen B, Laurent R. Prevalence and Distribution of Vascular FDG Uptake on Positron Emission Tomography (PET)-CT in Patients Suspected of Having Giant Cell Arteritis – Interim Results from the Giant Cell Arteritis and PET Scan (GAPS) Study [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/prevalence-and-distribution-of-vascular-fdg-uptake-on-positron-emission-tomography-pet-ct-in-patients-suspected-of-having-giant-cell-arteritis-interim-results-from-the-giant-cell-arteritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-and-distribution-of-vascular-fdg-uptake-on-positron-emission-tomography-pet-ct-in-patients-suspected-of-having-giant-cell-arteritis-interim-results-from-the-giant-cell-arteritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology